Julius O Nyalwidhe1,2, Lucy R Betesh3, Thomas W Powers4, E Ellen Jones4, Krista Y White5, Tanya C Burch5,2, Jasmin Brooks4, Megan T Watson5,2, Raymond S Lance2, Dean A Troyer2, O John Semmes5,2, Anand Mehta3, Richard R Drake4. 1. Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA , USA. 2. The Leroy T. Canoles, Jr. Cancer Research Center, Eastern Virginia Medical School Norfolk, VA, USA. 3. Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virology, Drexel University College of Medicine, Doylestown, PA, USA. 4. Department of Cell and Molecular Pharmacology and Experimental Therapeutics, MUSC Proteomics Center, Medical University of South Carolina, Charleston, SC, USA. 5. Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA.
Abstract
PURPOSE: Using prostatic fluids rich in glycoproteins like prostate-specific antigen and prostatic acid phosphatase (PAP), the goal of this study was to identify the structural types and relative abundance of glycans associated with prostate cancer status for subsequent use in emerging MS-based glycopeptide analysis platforms. EXPERIMENTAL DESIGN: A series of pooled samples of expressed prostatic secretions (EPS) and exosomes reflecting different stages of prostate cancer disease were used for N-linked glycan profiling by three complementary methods, MALDI-TOF profiling, normal-phase HPLC separation, and triple quadropole MS analysis of PAP glycopeptides. RESULTS: Glycan profiling of N-linked glycans from different EPS fluids indicated a global decrease in larger branched tri- and tetra-antennary glycans. Differential exoglycosidase treatments indicated a substantial increase in bisecting N-acetylglucosamines correlated with disease severity. A triple quadrupole MS analysis of the N-linked glycopeptides sites from PAP in aggressive prostate cancer pools was done to cross-reference with the glycan profiling data. CONCLUSION AND CLINICAL RELEVANCE: Changes in glycosylation as detected in EPS fluids reflect the clinical status of prostate cancer. Defining these molecular signatures at the glycopeptide level in individual samples could improve current approaches of diagnosis and prognosis.
PURPOSE: Using prostatic fluids rich in glycoproteins like prostate-specific antigen and prostatic acid phosphatase (PAP), the goal of this study was to identify the structural types and relative abundance of glycans associated with prostate cancer status for subsequent use in emerging MS-based glycopeptide analysis platforms. EXPERIMENTAL DESIGN: A series of pooled samples of expressed prostatic secretions (EPS) and exosomes reflecting different stages of prostate cancer disease were used for N-linked glycan profiling by three complementary methods, MALDI-TOF profiling, normal-phase HPLC separation, and triple quadropole MS analysis of PAPglycopeptides. RESULTS:Glycan profiling of N-linked glycans from different EPS fluids indicated a global decrease in larger branched tri- and tetra-antennary glycans. Differential exoglycosidase treatments indicated a substantial increase in bisecting N-acetylglucosamines correlated with disease severity. A triple quadrupole MS analysis of the N-linked glycopeptides sites from PAP in aggressive prostate cancer pools was done to cross-reference with the glycan profiling data. CONCLUSION AND CLINICAL RELEVANCE: Changes in glycosylation as detected in EPS fluids reflect the clinical status of prostate cancer. Defining these molecular signatures at the glycopeptide level in individual samples could improve current approaches of diagnosis and prognosis.
Authors: Steven R Barthel; Georg K Wiese; Jaehyung Cho; Matthew J Opperman; Danielle L Hays; Javed Siddiqui; Kenneth J Pienta; Bruce Furie; Charles J Dimitroff Journal: Proc Natl Acad Sci U S A Date: 2009-11-04 Impact factor: 11.205
Authors: Krista Y White; Lucy Rodemich; Julius O Nyalwidhe; Mary Ann Comunale; Mary Ann Clements; Raymond S Lance; Paul F Schellhammer; Anand S Mehta; O John Semmes; Richard R Drake Journal: J Proteome Res Date: 2009-02 Impact factor: 4.466
Authors: Haiying Li; Viral Patel; Shannon E DiMartino; John W Froehlich; Richard S Lee Journal: Mol Cell Proteomics Date: 2020-07-31 Impact factor: 5.911
Authors: Amit Kumar; Deniz Baycin-Hizal; Joseph Shiloach; Michael A Bowen; Michael J Betenbaugh Journal: Proteomics Clin Appl Date: 2015-01-19 Impact factor: 3.603
Authors: Shu-Min Zhou; Li Cheng; Shu-Juan Guo; Yang Wang; Daniel M Czajkowsky; Huafang Gao; Xiao-Fang Hu; Sheng-Ce Tao Journal: Breast Cancer Res Date: 2015-03-11 Impact factor: 6.466